BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 17972527)

  • 1. Hypofractionated accelerated radiochemotherapy with cytoprotection (Chemo-HypoARC) for inoperable non-small cell lung carcinoma.
    Koukourakis MI; Patlakas G; Froudarakis ME; Kyrgias G; Skarlatos J; Abatzoglou I; Bougioukas G; Bouros D
    Anticancer Res; 2007; 27(5B):3625-31. PubMed ID: 17972527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypofractionated/accelerated radiotherapy with cytoprotection (HypoARC) combined with vinorelbine and liposomal doxorubicin for locally advanced non-small cell lung cancer (NSCLC).
    Tsoutsou PG; Froudarakis ME; Bouros D; Koukourakis MI
    Anticancer Res; 2008; 28(2B):1349-54. PubMed ID: 18505077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radical hypofractionated accelerated radiotherapy with cytoprotection for invasive bladder cancer.
    Koukourakis MI; Tsolos C; Touloupidis S
    Urology; 2007 Feb; 69(2):245-50. PubMed ID: 17320657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High dose daily amifostine and hypofractionated intensively accelerated radiotherapy for locally advanced breast cancer. A phase I/II study and report on early and late sequellae.
    Koukourakis MI; Yannakakis D
    Anticancer Res; 2001; 21(4B):2973-8. PubMed ID: 11712796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. From conventionally fractionated radiation therapy to hyperfractionated radiation therapy alone and with concurrent chemotherapy in patients with early-stage nonsmall cell lung cancer.
    Jeremić B; Milicić B
    Cancer; 2008 Feb; 112(4):876-84. PubMed ID: 18172901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypofractionated and accelerated radiotherapy with amifostine cytoprotection (HypoARC): a new concept in radiotherapy and encouraging results in breast cancer.
    Koukourakis MI
    Semin Oncol; 2002 Dec; 29(6 Suppl 19):42-6. PubMed ID: 12577243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Postmastectomy hypofractionated and accelerated radiation therapy with (and without) subcutaneous amifostine cytoprotection.
    Koukourakis MI; Panteliadou M; Abatzoglou IM; Sismanidou K; Sivridis E; Giatromanolaki A
    Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):e7-13. PubMed ID: 23040218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Individualization of the subcutaneous amifostine dose during hypofractionated / accelerated radiotherapy.
    Koukourakis MI; Abatzoglou I; Sivridis L; Tsarkatsi M; Delidou H
    Anticancer Res; 2006; 26(3B):2437-43. PubMed ID: 16821629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973).
    Belderbos J; Uitterhoeve L; van Zandwijk N; Belderbos H; Rodrigus P; van de Vaart P; Price A; van Walree N; Legrand C; Dussenne S; Bartelink H; Giaccone G; Koning C;
    Eur J Cancer; 2007 Jan; 43(1):114-21. PubMed ID: 17084621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Feasibility of high-dose three-dimensional radiation therapy in the treatment of localised non-small-cell lung cancer.
    Bellière A; Girard N; Chapet O; Khodri M; Kubas A; Souquet PJ; Mornex F
    Cancer Radiother; 2009 Jul; 13(4):298-304. PubMed ID: 19525134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conformal hypofractionated and accelerated radiotherapy with cytoprotection (HypoARC) for high risk prostatic carcinoma: rationale, technique and early experience.
    Koukourakis MI; Touloupidis S; Manavis J; Abatzoglou I; Sismanidou K; Sivridis L
    Anticancer Res; 2004; 24(5B):3239-43. PubMed ID: 15510617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypofractionated accelerated radiotherapy, cytoprotection and capecitabine in the treatment of rectal cancer: a feasibility study.
    Koukourakis MI; Simopoulos C; Pitiakoudis M; Lyratzopoulos N; Romanidis K; Giatromanolaki A; Polychronidis A; Kouklakis G; Sivridis E; Minopoulos G; Manolas K
    Anticancer Res; 2008; 28(5B):3035-40. PubMed ID: 19031952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accelerated radical radiotherapy for non-small cell lung cancer using two common regimens: a single-centre retrospective study of outcome.
    Pemberton LS; Din OS; Fisher PM; Hatton MQ
    Clin Oncol (R Coll Radiol); 2009 Apr; 21(3):161-7. PubMed ID: 19111452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Phase II study of synchronous three-dimensional conformal boost to the gross tumor volume for patients with unresectable Stage III non-small-cell lung cancer: results of Korean Radiation Oncology Group 0301 study.
    Cho KH; Ahn SJ; Pyo HR; Kim KS; Kim YC; Moon SH; Han JY; Kim HT; Koom WS; Lee JS
    Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1397-404. PubMed ID: 19117690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postoperative pelvic hypofractionated accelerated radiotherapy with cytoprotection (HypoARC) for high-risk or recurrent prostate cancer.
    Koukourakis MI; Papadopoulou A; Abatzoglou I; Panteliadou M; Sismanidou K; Touloupidis S
    Anticancer Res; 2012 Oct; 32(10):4561-8. PubMed ID: 23060587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Computed tomography assessment of lung density in patients with lung cancer treated with accelerated hypofractionated radio-chemotherapy supported with amifostine.
    Koukourakis MI; Tsoutsou PG; Abatzoglou I
    Am J Clin Oncol; 2009 Jun; 32(3):258-61. PubMed ID: 19349852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical investigation of weekly Carboplatin and Paclitaxel with concurrent radiation therapy for locally advanced non-small cell lung cancer].
    Mito A; Yamasaki M; Matsuura K; Kajihara T; Nitta T; Awaya H; Arita K; Kashiwado K; Ohashi N
    Gan To Kagaku Ryoho; 2009 Oct; 36(10):1653-6. PubMed ID: 19838022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized phase 2 study of subcutaneous amifostine versus epoetin-alpha given 3 times weekly during concurrent chemotherapy and hyperfractionated radiotherapy for limited-disease small cell lung cancer.
    Han HS; Han JY; Yu SY; Pyo HR; Kim HY; Cho KH; Lee DH; Kim HT; Lee JS
    Cancer; 2008 Oct; 113(7):1623-31. PubMed ID: 18671241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I study of combination S-1 plus cisplatin chemotherapy with concurrent thoracic radiation for locally advanced non-small cell lung cancer.
    Chikamori K; Kishino D; Takigawa N; Hotta K; Nogami N; Kamei H; Kuyama S; Gemba K; Takemoto M; Kanazawa S; Ueoka H; Segawa Y; Takata S; Tabata M; Kiura K; Tanimoto M;
    Lung Cancer; 2009 Jul; 65(1):74-9. PubMed ID: 19056143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicentre phase II trial of paclitaxel and carboplatin with concurrent radiotherapy in locally advanced non-small cell lung cancer.
    Tell R; Sederholm C; Klintenberg C; Franksson L; Brandén E; Hillerdal G; Lönn U; Lindén CJ; Ewers SB; Lamberg K; Mrazek E; Lödén B; Sjögren A; Linné T; Friesland S; Sirzén F
    Anticancer Res; 2008; 28(5B):2851-7. PubMed ID: 19031924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.